Versant Ventures

Versant Ventures Research Investment Thesis Versant Ventures is a leading healthcare and biotechnology venture capital firm committed to helping exceptional entrepreneurs build the next generation of great companies. Founded in 1999 at the end of the Dot-com bubble by former partners from Brentwood Associates, Versant has evolved into one of the most prominent biotech VCs globally. The firm believes in combining deep scientific expertise with operational excellence to identify and accelerate breakthrough therapeutic and diagnostic innovations across the healthcare spectrum. Versant's core thesis centers on partnering with academic founders and experienced biotech teams to transform scientific discoveries into commercial enterprises. The firm brings not just capital but also industry expertise, operational resources, and access to its unique Discovery Engines—in-house laboratories staffed with multi-disciplinary scientists who actively participate in company creation. Sector Focus Versant is exclusively focused on biotech and life sciences investments: Drug discovery and development (small molecules, biologics, macrocyclic peptides) Therapeutic modalities: immunology, oncology, autoimmune disease, drug delivery Medical devices and diagnostics Healthcare IT and digital health Precision medicine and biomarkers Platform technologies enabling drug development The firm is ranked #5 among the top biotech VCs globally and is consistently featured in "top 10 biotech venture firms" lists alongside Flagship Pioneering, Third Rock Ventures, and ARCH Venture Partners. Stage Focus Versant invests across all stages from seed through post-IPO: Seed: Early-stage biotech companies with promising technology or academic partnerships Series A: Companies with validated technology and initial development data Series B+: Later-stage companies de-risking path to clinic or commercialization Growth and post-IPO: Follow-on investments in public companies The firm has no rigid stage preference but instead focuses on compelling science and founding teams regardless of stage. Check Size Typical investment range: $1M - $50M Seed/early-stage: Generally $1M-$10M Series A: $5M-$20M Later stages: $10M-$50M+ Follow-on reserve capacity: Significant reserves for follow-on investments Versant's largest fund (Fund VII or later) indicates very large check-writing capacity and willingness to lead major rounds. Lead Tendency Versant typically leads or co-leads rounds in which they participate. Their founding of Discovery Engines and active laboratory participation demonstrates a "hands-on leader" approach rather than passive investment. They frequently co-invest with other established biotech VCs (Flagship, Third Rock, etc.) but maintain control and board seats. Recent Activity Versant has been actively deploying capital through 2025: November 2025: Launched Dayra Therapeutics with $70M in total funding and a foundational $50M research partnership with Biogen. Dayra is developing oral macrocyclic peptides for immunology and other therapeutic areas—a strategic new modality for the firm. September 2025: Participated in $50M Series A for AllRock Bio, a company developing pan-ROCK inhibitor therapies for fibrotic diseases. Q3-Q4 2025: Multiple seed and early-stage investments including Gate Bioscience and others. Recent exits: Consistently delivers strong returns with 50+ IPOs and 50+ M&A exits in portfolio history. Notable recent exits include companies acquired by or partnering with major pharma (Biogen, Abbvie, Bristol Myers Squibb partnerships announced). Portfolio Highlights Notable Versant-backed companies: Crinetics Pharmaceuticals - Small-molecule endocrinology, publicly traded Saegis Pharmaceuticals - Oncology, recent news mentions Monte Rosa Therapeutics - Protein degradation platform Hotspur Technologies - High-profile biotech Granite Bio - Launched April 2025 from Ridgeline Discovery Engine with $100M funding, focused on autoimmune disease antibodies Dayra Therapeutics - Recent 2025 launch, oral macrocyclic peptides with Biogen partnership AllRock Bio - Pan-ROCK inhibitors, $50M Series A Bright Peak Therapeutics - Cytokine company from Ridgeline SixPeaks Bio AG - Launched 2022 from Ridgeline with $110M funding Black Diamond Therapeutics - First company launched from Ridgeline (2018) Quentis Therapeutics - Launched from Highline Discovery Engine with $48M Series A Discovery Engines (Unique Model) Versant operates three Discovery Engines—in-house R&D laboratories that enable company creation: Ridgeline Therapeutics (Basel, Switzerland): Operational since 2017, Ridgeline is headquartered in Basel Technology Park and has access to strong European academic research plus major pharmaceutical partners. The team includes accomplished industry R&D veterans running state-of-the-art laboratory facilities. Ridgeline has launched multiple companies including Black Diamond Therapeutics, Bright Peak, SixPeaks Bio, and Granite Bio. Highline Therapeutics (New York, NY): Based in partnership with Weill Cornell Medicine, Highline creates and seeds biotech companies from academic discoveries. Notable companies include Quentis Therapeutics ($48M Series A) and others. Third Discovery Engine: Implied by references to "3 Discovery Engines" and "3 locations" with discovery capabilities (likely including Bay Area/California operations). This Discovery Engine model is unique in venture capital and represents a key competitive advantage. Versant invests "tens of millions" seeding companies from these labs, re-running key experiments, and importing big-pharma discipline into venture-backed biotech. Team Versant's investment team combines exceptional depth and breadth: Managing Directors: Brad Bolzon, Ph.D. - Chairman and Managing Director, architect of firm strategy Jerel Davis, Ph.D. - Managing Director based in Canada Alex Mayweg, Ph.D. - Managing Director, architect of Ridgeline Discovery Engine Clare Ozawa, Ph.D. - Managing Director, leads San Diego and Bay Area investments Carlo Rizzuto, Ph.D. - Managing Director, New York-based Tom Woiwode, Ph.D. - Managing Director Partners: Markus Enzelberger, Ph.D. Nigel Sheail Venture Partners & Other Roles: 10+ Venture Partners (Ph.D., M.D., industry veterans) 4+ Principals (rising investment leadership) Operating Partners (operational expertise) CBO-in-Residence Entrepreneur-in-Residence (Rick Dewey, M.D.) Operations: Robin Praeger - Managing Director and CFO Max Eisenberg - Chief Operating Officer Steven Edelson - Vice President, Investor Relations and Communications The team collectively brings 100+ years of VC experience, 60+ years of pharmaceutical experience, and 45+ years of biotech experience. Geographic Focus Versant has multiple office locations: San Francisco, CA - Headquarters Menlo Park, CA - Bay Area operations New York, NY - Highline Discovery Engine and NYC investments Basel, Switzerland - Ridgeline Discovery Engine Canada - Dedicated team led by Managing Director Jerel Davis Additional locations (implied by "6 locations" reference) Geographic strategy: US-focused with selective international investments in Europe (especially Switzerland for Ridgeline) and Canada. Primary investment regions: Northern California, New York, and Canada, with European access through Ridgeline. Academic Partnerships Versant maintains 30+ academic partnerships globally that feed discovery engines and sourcing pipeline. Major partnerships with: Weill Cornell Medicine (Highline partnership) European academic institutes (Ridgeline relationships) US and Canadian research institutions Decision Process Versant employs a partnership-based decision model: Investment decisions made by Managing Director partnership Board seats and active monitoring typical Scientific diligence conducted by Discovery Engine teams Commercial assessment by investment team No single-partner veto; consensus-driven but decisive Decision Timeline Not explicitly documented but implied 6-12 week timeline based on depth of due diligence (scientific + commercial + operational). Warm Introductions Versant strongly prefers warm introductions through academic relationships, existing founders, or partners. Direct outreach possible but lower probability of engagement. Typical Involvement Versant takes board seats and active operational roles: Board representation: Standard Advisory support: Active through Discovery Engine teams Network access: Strong relationships with pharma (Biogen, Abbvie, BMS partnerships) M&A support: Leveraged through pharma partnerships and network Fund Status Versant is in active deployment phase. Fund VII (most recent major fund) or later is actively deploying capital. Recent 2025 launches and Series A participation indicate strong deployment velocity and continued fundraising capacity. Competitive Positioning Versant is consistently ranked in the top 5 biotech VCs alongside: Third Rock Ventures Flagship Pioneering ARCH Venture Partners Atlas Venture 5AM Ventures Key differentiators: Discovery Engines model (unique in industry) 25+ year track record since 1999 International geographic presence Deep pharma partnerships Multi-stage investment capacity Founder Preferences Versant actively backs: Academic founders with strong scientific credentials Experienced biotech entrepreneurs with successful track records Teams with complementary science + business expertise Founders committed to building sustainable, profitable companies Companies focusing on "serious diseases" with significant commercial opportunity Exit Strategy Versant targets: Acquisition by major pharmaceutical companies (preferred for most deals) IPO (for larger, platform-technology companies) Private equity recapitalization (less common) Historically: 50+ IPOs, 50+ M&A exits Notable Context Versant's description in F4-OS database captures their unique model: "Creates and seeds about half its portfolio companies from in-house discovery labs (Ridgeline in Basel, Highline in New York), seeding them with tens of millions and re-running key experiments, importing big-pharma discipline into venture-backed biotech." This is the definitive competitive advantage and differentiator in biotech VC.